BioElectronics Corporation's New Commercial Airing Nationally Advertising Initiative Will Reach 15,000,000 Homes Nationwide

BioElectronics Corporation's New Commercial Airing Nationally Advertising Initiative Will Reach 15,000,000 Homes Nationwide

FREDERICK, Md., April 9, 2008 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that the company will start airing a new commercial for its ActiPatch (TM) technology on Bloomberg Television, April 14, 2008. The company has initiated an advertising contract that calls for the informational commercial to run for the next two weeks, and will reach millions of viewers daily. CEO Andrew Whelan comments, "This is a new initiative for BioElectronics Corporation and we are excited that this commercial will inform consumers, physicians, and distributors about our ActiPatch(TM) products. This national advertisement should help us reach a new level in both product and brand awareness."

The new bio-electronic super-bandage has produced significant rapid healing results in trials and has already received regulatory clearance by the FDA for the treatment of edema following blepharoplasty.

"ActiPatch (TM)" is very thin, easily applied and comfortable to wear on an injured area. The patch effectively minimizes pain and swelling. Physicians are so impressed with the power of the patch that they are providing it to their patients for uses beyond plastic surgery recovery. Trials are ongoing in multiple areas.

The new ActiPatch(TM) retail product line targets five common conditions that affect hundreds of millions of people throughout the world: 1) Back pain, 2) Foot and ankle pain, including ankle sprains and plantar fasciitis, 3) Knee pain, 4) Arm and wrist pain, including carpal tunnel and tennis elbow. BioElectronics has planned an aggressive retail introduction of these products for locations outside of the United States where regulatory clearance has been received. Distribution is expected in Canada, Italy, Netherlands, Australia, Mexico, United Kingdom, the Middle East, and other countries over the next few months.

About BioElectronics

BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatch(TM) is a drug free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch(TM) delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling.

For more information visit:

http://www.bioelectronicscorp.com/

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

First Call Analyst:
FCMN Contact: Annise.rice@actipatch.net

Source: BioElectronics Corporation

CONTACT: Patricia Baker, The Big Picture Agency LLC, +1-413-623-0950
ext. 221, pbaker@bigpictureagency.com, Investor Relations, Joe Noel, Emerging
Growth Research LLP, +1-925-922-2560, jnoel701@yahoo.com, both for
BioElectronics Corporation

Web site:

http://www.bioelectronicscorp.com/

-------
Profile: intent